| abstract |
The present invention provides the identification of biomarker gene sets whose expression levels are useful for evaluating and classifying biological samples to determine exposure to a biological active dose of a Wee 1 inhibitor, early prediction of response to a cancer therapy treatment, and pre-dose exposure prediction of sensitivity or resistance of a sample to Wee 1 inhibitor, among other uses. The present invention also provided a method for predicting a response to a cancer therapy treatment with a Wee 1 inhibitor by determining expression levels of the biomarker gene set. |